Quarterly ResultMay 13, 2026, 04:08 PM
SeaStar Medical Q1 Revenue +69% to $0.5M; Expands QUELIMMUNE Base
AI Summary
SeaStar Medical reported a 69% increase in first-quarter 2026 net revenue to $0.5 million, driven by the expansion of its QUELIMMUNE pediatric AKI customer base to 17 top-rated children's hospitals. The company also advanced enrollment in its NEUTRALIZE-AKI pivotal trial for adult AKI, with 198 of 339 patients enrolled, and initiated efforts for a modular post-marketing application (PMA) submission. Additionally, SeaStar Medical completed enrollment in the SAVE Registry and published positive real-world data for QUELIMMUNE, showing a 76% survival rate at 60 days.
Key Highlights
- Q1 2026 net revenue increased 69% to $0.5 million from $0.3 million in Q1 2025.
- Added 7 new children's hospitals, expanding QUELIMMUNE customer base to 17.
- NEUTRALIZE-AKI pivotal trial enrolled 198 of 339 adult AKI patients.
- Completed enrollment of 50 patients in the SAVE Registry for QUELIMMUNE.
- Published real-world QUELIMMUNE data showing 76% survival at 60 days.
- Initiated efforts for modular PMA submission for adult AKI indication.
- Q1 2026 net loss was $3.5 million, or $0.90 per share.
- Cash and equivalents stood at $9.3 million as of March 31, 2026.